Beta-blockers for hypertension (Q24243099)

1

C S

Wiysonge

1 reference

30 October 2023

Hazel A Bradley

2

H

Bradley

1 reference

30 October 2023

Roy T Maroney

4

R

Maroney

1 reference

30 October 2023

Anthony Mbewu

5

A

Cochrane Database of Systematic Reviews

Mbewu

1 reference

30 October 2023

24 January 2007

0 references

published in

0 references

cites work

Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint Reduction in Hypertension.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB2

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB2

Nebivolol: a third-generation beta-blocker that augments vascular nitric oxide release: endothelial beta(2)-adrenergic receptor-mediated nitric oxide production

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB2

Science, medicine, and the future. Hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB2

Re-examining the efficacy of beta-blockers for the treatment of hypertension: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB2

Evidence is needed that beta blockade alone reduces mortality in hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB2

Randomised, double blind, multicentre comparison of hydrochlorothiazide, atenolol, nitrendipine, and enalapril in antihypertensive treatment: results of the HANE study. HANE Trial Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB2

Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB2

British Hypertension Society guidelines for hypertension management 1999: summary

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB2

Are β-Blockers Efficacious as First-line Therapy for Hypertension in the Elderly?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB2

7 January 2021

Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB2

7 January 2021

Principal Results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) Trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB2

7 January 2021

A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB2

7 January 2021

The international prospective primary prevention study in hypertension (IPPPSH): objectives and methods. The IPPPSH Collaborative Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB2

7 January 2021

The Medical Research Council Hypertension Trial: the smoking patient

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB2

7 January 2021

Beta-blockers versus saluretics in hypertension. Comparison of total mortality, myocardial infarction, and sudden death: study design and early results on blood pressure reduction

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB2

7 January 2021

Blood pressure, stroke, and coronary heart disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB2

7 January 2021

Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension)

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB2

7 January 2021

Meta-analysis in clinical trials

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB2

7 January 2021

The role of the new beta-blockers in treating cardiovascular disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB2

7 January 2021

Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB2

7 January 2021

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB2

7 January 2021

Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB2

7 January 2021

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre ra

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB2

7 January 2021

Atenolol in hypertension: is it a wise choice?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB2

7 January 2021

Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (A

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB2

7 January 2021

Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB2

7 January 2021

beta-blockers or diuretics in hypertension? A six year follow-up of blood pressure and metabolic side effects

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB2

7 January 2021

Blood-pressure control in the hypertensive population

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB2

7 January 2021

Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB2

7 January 2021

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB2

7 January 2021

Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB2

7 January 2021

Design and baseline characteristics of participants in the African American Study of Kidney Disease and Hypertension (AASK) Pilot Study.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB2

7 January 2021

Rationale and design for the Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints (CONVINCE) Trial.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB2

7 January 2021

Evidence-based evaluation of calcium channel blockers for hypertension: equality of mortality and cardiovascular risk relative to conventional therapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB2

7 January 2021

Rationale and design of the International Verapamil SR/Trandolapril Study (INVEST): an Internet-based randomized trial in coronary artery disease patients with hypertension

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB2

7 January 2021

β-blockers in hypertension—the emperor has no clothes: an open letter to present and prospective drafters of new guidelines for the treatment of hypertension

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB2

7 January 2021

Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB2

7 January 2021

Primary prevention of sudden cardiovascular death in hypertensive patients. Mortality results from the MAPHY Study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB2

7 January 2021

STOP-hypertension: Swedish trial in old patients with hypertension.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB2

7 January 2021

Beta-blockers versus diuretics in hypertensive men: main results from the HAPPHY trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB2

7 January 2021

The Captopril Prevention Project: a prospective intervention trial of angiotensin converting enzyme inhibition in the treatment of hypertension. The CAPPP Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB2

7 January 2021

Antihypertensive efficacy and side effects of three beta-blockers and a diuretic in elderly hypertensives: a report from the STOP-Hypertension study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB2

7 January 2021

Risk factors associated with alterations in carotid intima-media thickness in hypertension: baseline data from the European Lacidipine Study on Atherosclerosis.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB2

7 January 2021

Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. ASCOT investigators

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB2

7 January 2021

Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB2

7 January 2021

Old antihypertensives and new diabetes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB2

7 January 2021

Evidence-based medicine in hypertension: what type of evidence?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB2

7 January 2021

How strong is the evidence for use of beta-blockers as first-line therapy for hypertension? Systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB2

7 January 2021

Low-dose antihypertensive treatment with a thiazide diuretic is not diabetogenic. A 10-year controlled trial with bendroflumethiazide.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB2

7 January 2021

MRC trial of treatment of mild hypertension: principal results. Medical Research Council Working Party

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB2

7 January 2021

Randomised trial of treatment of hypertension in elderly patients in primary care

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB2

7 January 2021

Measuring inconsistency in meta-analyses

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB2

7 January 2021

Coronary heart disease in the Medical Research Council trial of treatment of mild hypertension. Medical Research Council Working Party on Mild Hypertension

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB2

7 January 2021

Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB2

7 January 2021

Third-generation beta-blockers stimulate nitric oxide release from endothelial cells through ATP efflux: a novel mechanism for antihypertensive action

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB2

7 January 2021

Adverse prognostic significance of new diabetes in treated hypertensive subjects

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB2

7 January 2021

Clinical outcomes in the diabetes cohort of the INternational VErapamil SR-Trandolapril study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB2

7 January 2021

Angiotensin-Converting Enzyme Inhibitors and Calcium Channel Blockers for Coronary Heart Disease and Stroke Prevention

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB2

7 January 2021

Decreased coronary heart disease in hypertensive smokers. Mortality results from the MAPHY study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB2

7 January 2021

Metoprolol versus thiazide diuretics in hypertension. Morbidity results from the MAPHY Study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB2

7 January 2021

Trial of secondary prevention with atenolol after transient ischemic attack or nondisabling ischemic stroke. The Dutch TIA Trial Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB2

7 January 2021

Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB2

7 January 2021

Rethinking the "diseases of affluence" paradigm: global patterns of nutritional risks in relation to economic development

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB2

7 January 2021

The Nordic Diltiazem Study (NORDIL). A prospective intervention trial of calcium antagonist therapy in hypertension

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002003.PUB2

7 January 2021